ErythroSIMNCT05559827
Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismatch After Allogeneic Hematopoietic Stem Cell Transplantation
StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2022); last known: Not Yet Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
time interval between randomization (corresponding to the M6 post-transplant) and resolution of PRCA (date of resolution of reticulocytopenia) treated or not by the anti-CD 38 monoclonal antibody isatuximab
Timeframe: 9 months post randomization
Secondary (9)
Number of red blood cell transfusions after randomization
Ferritin levels
Adverse events (CTC-AE grade ≥ 2)
Quality of life questionnaire (EORTC QLQ-C30- v3)
Spontaneous resolution of PRCA between day 60 and 6 months post-transplant
Show 4 moreShow less
Antibody level (anti A and/or anti B titers)
Number of days of hospitalization
Number of days of transfusions support
Number of days of chelation treatments
Arms and interventions
Isatuximab armExperimental
Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes \<10 G / L, and a third at day 29 if reticulocytes \<10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
comparator armNo intervention
No treatment, supportive care will be allowed.
Drugs: Isatuximab